Skandinaviska Enskilda Banken AB publ Has $29.15 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Skandinaviska Enskilda Banken AB publ boosted its position in Moderna, Inc. (NASDAQ:MRNA) by 0.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 245,687 shares of the company’s stock after buying an additional 706 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.06% of Moderna worth $29,150,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Ontario Teachers Pension Plan Board bought a new stake in shares of Moderna during the fourth quarter valued at approximately $1,358,000. Hobbs Group Advisors LLC acquired a new position in Moderna during the fourth quarter worth $664,000. Illinois Municipal Retirement Fund raised its holdings in Moderna by 22.1% during the first quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company’s stock worth $5,519,000 after buying an additional 9,360 shares during the last quarter. Swedbank AB bought a new position in shares of Moderna in the first quarter valued at $3,315,000. Finally, Wellington Management Group LLP grew its holdings in shares of Moderna by 28.8% during the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after buying an additional 1,614,460 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Down 3.4 %

Shares of NASDAQ MRNA opened at $65.69 on Friday. The business’s fifty day moving average price is $90.07 and its 200-day moving average price is $110.76. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47. The stock has a market capitalization of $25.18 billion, a PE ratio of -4.19 and a beta of 1.68. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. During the same quarter last year, the business earned ($3.62) earnings per share. The company’s quarterly revenue was down 29.9% on a year-over-year basis. On average, equities research analysts anticipate that Moderna, Inc. will post -9.52 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Barclays dropped their price target on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating on the stock in a research report on Monday, September 16th. Oppenheimer lowered Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Hsbc Global Res upgraded Moderna from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 28th. Piper Sandler dropped their price objective on Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, September 13th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and cut their price objective for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $100.44.

Insider Activity at Moderna

In other Moderna news, President Stephen Hoge sold 15,000 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the sale, the president now owns 1,442,089 shares in the company, valued at $174,665,819.68. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the sale, the president now directly owns 1,442,089 shares in the company, valued at approximately $174,665,819.68. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The disclosure for this sale can be found here. In the last ninety days, insiders sold 93,158 shares of company stock worth $11,167,312. Corporate insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.